Novavax (NVAX) Stock Forecast & Price Target

Novavax is attractive because its Matrix-M adjuvant appears to be a differentiated, human-use-approved immune stimulant with broad applicability and a potentially cleaner safety profile than competing approaches, which could support multiple future vaccine programs. The recent Sanofi collaboration, along with four additional MTAs and partnerships with four top-ten global pharmaceutical companies across 30+ fields, suggests external validation of the platform and a credible path to royalty-bearing value creation. Financially, the Nuvaxovid franchise still offers meaningful upside through high-teens to low-20s royalties, while modeled Sanofi-led U.S. and EU combo revenues of $670.0MM and $560.0MM indicate material commercial leverage if adoption and immunogenicity data continue to track favorably.

Novavax is facing a weakening demand backdrop as surveyed physicians expected an 11% decline in U.S. COVID-19 boosters in the 2026-27 season, while IQVIA data already indicated about a 26% decline in COVID-19 vaccine prescriptions through 12/26/25. The outlook is further pressured by New FDA/CDC guidelines implemented in '25 that limit access for adults without risk factors, alongside uncertainty around standalone COVID-19 share in 2030 of just 19% to 26% for Nuvaxovid, suggesting limited pricing power and modest market penetration. As a clinical-stage biotech, it also remains exposed to regulatory delays, safety signals, IP challenges, and the risk that failed combo or variant-specific boosters could undermine future value creation.